ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Promis financing

<< Previous

Bullboard Posts

Next >>

Post by bball67on Jul 13, 2021 10:39am

305 Views

Post# 33535531

Promis financing

I believe the stock is ready to take off. Increased my stake today, now at 1.1M shares. I believe the approved shelf offering will pretty quickly lead to a financing backed and led by the Boston Group. Believe the financing will be significant and will enable us to ramp up to, and begin Phase 1 clinical trials. This is the logical outcome of the Boston group initial investment and the approved shelf offering. Also believe the appointment of Neil Warma to Board may lead to him being new CEO. The appointment of Dr. Tanzi to chair of scientifc board is another tell that something big is about to happen. This is just my opinion.

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price